[Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018002899
German
Original Title:
Rilpivirin/Emtricitabin/Tenofovir
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a12-02.html
Year Published:
2012
URL for published report:
https://www.iqwig.de/download/A12-02_Rilpivirin-Emtricitabin-Tenofovir_Nutzenbewertung_35a_SGB_V.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- HIV
- HIV Infections
- Anti-HIV Agents
- Reverse Transcriptase Inhibitors
- Rilpivirine
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- Drug Therapy, Combination
Keywords
- Rilpivirine
- Emtricitabine
- Tenofovir Disoproxil
- Human Immunodeficiency Virus Type 1
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.